McNeil mobilizes ADHD awareness in NYC

Share this article:
McNeil mobilizes ADHD awareness in NYC
McNeil mobilizes ADHD awareness in NYC
Pedestrians mulling around Times Square in New York City can learn more about ADHD by responding to an advertisement on the CBS jumbotron, via text message.

The 15-second ad reads, “Can't focus? Can't sit still? Could you or your child have ADHD? To find out more, text ‘ADHD' to 87415,” and can be seen on the 26x20 foot screen four times per hour, according to Tricia Geoghegan, a McNeil Pediatrics spokesperson. The jumbotron ads will run through November 30.

Upon texting “ADHD” to the number 87415, consumers receive a near-instantaneous text message in return containing a link to the “Concerta Mobile Web Experience,” a branded mobile-optimized platform for McNeil's ADHD drug. The mobile site offers information about ADHD in adults and children, an ADHD/ADD screening adapted from the World Health Organization's ADHD test, branded testimonial videos and a coupon offering a 30-day free trial of Concerta. At press time, 4,764 consumers had accessed the Concerta mobile web program, according to Geoghegan.

Although the Times Square billboard offers plenty of exposure, Geoghegan said that creating a redirect for – a technology that sends mobile phone users straight to the mobile-optimized website when they attempt to access online – immediately brought the visitor numbers up to triple digits. “We went from 10 visits on October 5, to 516 visits on October 6,” said Geoghegan, adding that the company had known mobile users were trying to access from Google Analytics data. “We're learning from our users,” said Geoghegan.
NYC-based Augme Mobile, acquired by Modavox, Inc. in July, provided the texting platform, and Ogilvy Healthworld built the product site. McNeil Pediatrics is a subsidiary of Johnson & Johnson.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...